Gyermekkori daganatok: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 98
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• NF1 12
• ABL1 2
• HER2 25
• PI3K 5
• AKT 1
• CDK4/6 7
• PD-L1 13
• NTRK 10
• NMDA 0
• B7-H3 15
• mTOR 2
• RB1 1
• KMT2A 12
• PSMA 20
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• RAS 1
• CD38 5
• EZH2 0
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

56+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

  NCT04543188· Pfizer· Frissítve: 2025. okt. 23.

  “Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

  NCT03919071· National Cancer Institute (NCI)· Forrás

• Dabrafenib and/or Trametinib Rollover Study

  NCT03340506· Novartis Pharmaceuticals· Forrás

• A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· Pfizer· Forrás

• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Cancer Research UK· Forrás

• A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

  NCT05217446· Pfizer· Forrás

• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  NCT05503797· Fore Biotherapeutics· Forrás

• DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

  NCT05722886· Cancer Research UK· Forrás

• Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

  NCT04417621· Novartis Pharmaceuticals· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 125
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 31
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 87
• Immunohistochemistry 197
• Liquid Biopsy 25
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 522
• Machine Learning 69
• Deep Learning 25
• Cohort Studies 328
• Genome-Wide Association Study 22

• Early Prediction of Cardiomyopathy in Pediatric Cancer Survivors Using Echocardiographic Video-Based Deep Learning.

  Echocardiography, 2026. okt.

• [Multicenter study of deep learning multitask model for predicting neoadjuvant chemotherapy response and event-free survival of pediatric head and neck rhabdomyosarcoma].

  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2026. szept.

• Biallelic loss of RB1 in hepatocellular carcinoma as synthetic lethal target for artificial intelligence-guided therapy.

  Signal Transduct Target Ther, 2026. aug.

• TFE3-DualNet: An Interpretable Foundation Model-Based Deep Learning Ensemble for Diagnosing TFE3-Rearranged Renal Cell Carcinoma From Whole-Slide Images in a Two-Center Cohort.

  Cancer Med, 2026. aug.

• Deep learning-based automated segmentation of target volumes for pediatric craniospinal irradiation in proton therapy.

  Radiat Oncol, 2026. júl.

• Deep learning for contrast-enhanced MRI in pediatric brain imaging.

  Neuroradiology, 2026. júl.

• The role of machine learning, deep learning, and MRI findings in the classification of pediatric posterior fossa tumors.

  Childs Nerv Syst, 2026. jún.

• Improving image quality and diagnostic confidence for PRETEXT staging in pediatric hepatoblastoma using thin-slice and low-energy virtual monochromatic images in dual-energy CT with deep learning image reconstruction algorithm.

  BMC Med Imaging, 2026. máj.

• A novel deep-learning approach for monitoring gastrointestinal air variation during radiotherapy in young patients using radiographs.

  Phys Med Biol, 2026. máj.

• Deep Learning-Based Analysis of Gene Expression Data and Gene-Related Information in Pediatric Surgical Oncology: A Scoping Review.

  Cancer Med, 2026. máj.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.